Targets › GPX3
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.
Protects cells and enzymes from oxidative damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, by glutathione. (UniProt, P22352)
Open in Phaseline: the race on GPX3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sound Pharmaceuticals | Ebselen (SPI-1005) Glutathione peroxidase mimetic | GPX1, GPX2, GPX3, GPX4 | Phase 3 | Meniere's Disease; Hearing Loss | Dec 2026 |
Meniere's Disease (1) Hearing Loss (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.